West Pharmaceutical Releases 2026 Financial Outlook
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2h ago
0mins
Should l Buy WST?
Source: seekingalpha
- Earnings Beat: West Pharmaceutical's Q4 Non-GAAP EPS of $2.04 exceeded expectations by $0.21, with revenue of $805 million reflecting a 7.5% year-over-year increase, indicating strong market performance.
- 2026 Sales Guidance: The company anticipates net sales for 2026 to range between $3.215 billion and $3.275 billion, assuming a mid-2026 close for the sale of SmartDose 3.5ml, showcasing confidence in future growth.
- Organic Growth Outlook: Expected organic net sales growth for 2026 is projected at 5% to 7%, with an estimated 2 percentage point benefit from current foreign exchange rates, enhancing the company's competitive position in the market.
- Capital Expenditure Plans: Projected capital expenditures for 2026 are expected to be between $250 million and $275 million, reflecting the company's commitment to future investments, while Q1 adjusted EPS is expected to grow by 13% to 16.4%.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy WST?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on WST
Wall Street analysts forecast WST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for WST is 348.70 USD with a low forecast of 285.00 USD and a high forecast of 375.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
10 Buy
2 Hold
0 Sell
Strong Buy
Current: 243.560
Low
285.00
Averages
348.70
High
375.00
Current: 243.560
Low
285.00
Averages
348.70
High
375.00
About WST
West Pharmaceutical Services, Inc. is a global manufacturer that is engaged in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. The Company operates in two segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers elastomers & primary containment, drug delivery devices, integrated solutions, and analytical lab services, primarily to biologic, generic, and pharmaceutical drug customers. The Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. This segment manufactures customer-owned components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
West Pharmaceutical to Announce Q4 Earnings on February 12
- Earnings Announcement: West Pharmaceutical (WST) is set to release its Q4 earnings on February 12 before market open, with consensus EPS estimate at $1.83, reflecting a 0.5% year-over-year increase, which could influence stock performance.
- Revenue Expectations: The anticipated revenue for Q4 is $794.8 million, representing a 6.1% year-over-year growth, and achieving this would further solidify the company's market position in the pharmaceutical sector.
- Performance Beat Record: Over the past two years, WST has exceeded EPS estimates 88% of the time and revenue estimates 75% of the time, showcasing its strong profitability and market adaptability.
- Revision Trends: In the last three months, EPS estimates have seen one upward revision and three downward adjustments, while revenue estimates experienced no upward revisions and two downward adjustments, indicating a cautious market outlook on the company's future performance.
See More
S&P 500 Futures Rise in Pre-Market Trading; Icon PLC and Baxter International Underperform
- Cognex Corp. Performance: Cognex Corp. (CGNX) saw a significant increase of 23.4% in pre-market trading.
- Zebra Technologies Corp. Performance: Zebra Technologies Corp. Cl A (ZBRA) experienced a rise of 11.3% in pre-market trading.
See More
West Pharmaceutical Services Reports Strong Q4 2025 Results and Guidance
- Strong Financial Performance: In Q4 2025, West Pharmaceutical Services reported net sales of $661.8 million, a 7.8% increase year-over-year, driven by double-digit adjusted earnings per share growth in its High-Value Product Components segment, showcasing the company's robust execution and growth potential in the market.
- Segment Growth Dynamics: The Contract-Manufactured Products segment saw a 6.2% sales increase to $143.2 million, with growth in self-injection devices for obesity and diabetes, although sales of healthcare diagnostic devices continued to decline, reflecting market demand diversity and challenges.
- Future Outlook: The company anticipates continued positive momentum in 2026, with adjusted earnings per share guidance ranging from $7.79 to $8.14, representing a 14.7% to 19.9% increase from 2025, indicating management's confidence in future performance.
- Global Market Impact: West Pharmaceutical Services achieved $3.07 billion in net sales for 2025, a 6.3% increase from 2024, which not only solidifies its leadership position in the global pharmaceutical industry but also provides funding for future investments and innovations.
See More
West Pharmaceutical Releases 2026 Financial Outlook
- Earnings Beat: West Pharmaceutical's Q4 Non-GAAP EPS of $2.04 exceeded expectations by $0.21, with revenue of $805 million reflecting a 7.5% year-over-year increase, indicating strong market performance.
- 2026 Sales Guidance: The company anticipates net sales for 2026 to range between $3.215 billion and $3.275 billion, assuming a mid-2026 close for the sale of SmartDose 3.5ml, showcasing confidence in future growth.
- Organic Growth Outlook: Expected organic net sales growth for 2026 is projected at 5% to 7%, with an estimated 2 percentage point benefit from current foreign exchange rates, enhancing the company's competitive position in the market.
- Capital Expenditure Plans: Projected capital expenditures for 2026 are expected to be between $250 million and $275 million, reflecting the company's commitment to future investments, while Q1 adjusted EPS is expected to grow by 13% to 16.4%.
See More
Stocks Close Steady Following Robust Jobs Data
Market Movement: The S&P 500 attempted to reach the 7,000 mark during trading.
End of Day Status: Despite the early gains, the index closed the day at its starting point.
See More
Key Focus Areas This Week: Jobs, Consumer Prices, Coca-Cola, CVS, Ford, McDonald's, and More
- Market Performance: The Dow Jones Industrial Average rose by 2.5% and closed above 50,000 for the first time.
- Nasdaq Struggles: In contrast, the Nasdaq Composite ended the week down 1.8%, despite a strong rally on Friday.
See More
West Pharmaceutical to Announce Q4 Earnings on February 12
- Earnings Announcement: West Pharmaceutical (WST) is set to release its Q4 earnings on February 12 before market open, with consensus EPS estimate at $1.83, reflecting a 0.5% year-over-year increase, which could influence stock performance.
- Revenue Expectations: The anticipated revenue for Q4 is $794.8 million, representing a 6.1% year-over-year growth, and achieving this would further solidify the company's market position in the pharmaceutical sector.
- Performance Beat Record: Over the past two years, WST has exceeded EPS estimates 88% of the time and revenue estimates 75% of the time, showcasing its strong profitability and market adaptability.
- Revision Trends: In the last three months, EPS estimates have seen one upward revision and three downward adjustments, while revenue estimates experienced no upward revisions and two downward adjustments, indicating a cautious market outlook on the company's future performance.
See More
S&P 500 Futures Rise in Pre-Market Trading; Icon PLC and Baxter International Underperform
- Cognex Corp. Performance: Cognex Corp. (CGNX) saw a significant increase of 23.4% in pre-market trading.
- Zebra Technologies Corp. Performance: Zebra Technologies Corp. Cl A (ZBRA) experienced a rise of 11.3% in pre-market trading.
See More
West Pharmaceutical Services Reports Strong Q4 2025 Results and Guidance
- Strong Financial Performance: In Q4 2025, West Pharmaceutical Services reported net sales of $661.8 million, a 7.8% increase year-over-year, driven by double-digit adjusted earnings per share growth in its High-Value Product Components segment, showcasing the company's robust execution and growth potential in the market.
- Segment Growth Dynamics: The Contract-Manufactured Products segment saw a 6.2% sales increase to $143.2 million, with growth in self-injection devices for obesity and diabetes, although sales of healthcare diagnostic devices continued to decline, reflecting market demand diversity and challenges.
- Future Outlook: The company anticipates continued positive momentum in 2026, with adjusted earnings per share guidance ranging from $7.79 to $8.14, representing a 14.7% to 19.9% increase from 2025, indicating management's confidence in future performance.
- Global Market Impact: West Pharmaceutical Services achieved $3.07 billion in net sales for 2025, a 6.3% increase from 2024, which not only solidifies its leadership position in the global pharmaceutical industry but also provides funding for future investments and innovations.
See More
West Pharmaceutical Releases 2026 Financial Outlook
- Earnings Beat: West Pharmaceutical's Q4 Non-GAAP EPS of $2.04 exceeded expectations by $0.21, with revenue of $805 million reflecting a 7.5% year-over-year increase, indicating strong market performance.
- 2026 Sales Guidance: The company anticipates net sales for 2026 to range between $3.215 billion and $3.275 billion, assuming a mid-2026 close for the sale of SmartDose 3.5ml, showcasing confidence in future growth.
- Organic Growth Outlook: Expected organic net sales growth for 2026 is projected at 5% to 7%, with an estimated 2 percentage point benefit from current foreign exchange rates, enhancing the company's competitive position in the market.
- Capital Expenditure Plans: Projected capital expenditures for 2026 are expected to be between $250 million and $275 million, reflecting the company's commitment to future investments, while Q1 adjusted EPS is expected to grow by 13% to 16.4%.
See More
Stocks Close Steady Following Robust Jobs Data
Market Movement: The S&P 500 attempted to reach the 7,000 mark during trading.
End of Day Status: Despite the early gains, the index closed the day at its starting point.
See More
Key Focus Areas This Week: Jobs, Consumer Prices, Coca-Cola, CVS, Ford, McDonald's, and More
- Market Performance: The Dow Jones Industrial Average rose by 2.5% and closed above 50,000 for the first time.
- Nasdaq Struggles: In contrast, the Nasdaq Composite ended the week down 1.8%, despite a strong rally on Friday.
See More
